Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2023-10-11 Share Issue/Capital Cha…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：关于股东部分股份解除质押的公告
Share Issue/Capital Change Classification · 100% confidence The document is a public announcement from Shanghai Medicilon Inc. regarding the partial release of pledged shares by a shareholder named Lin Changqing. It details the number of shares released from pledge, the remaining pledged shares, and their proportions relative to the shareholder's total holdings and the company's total share capital. The document is short (754 characters) and focuses on share pledge status changes, which is a capital structure related update. It does not contain financial statements, management discussion, or audit information. It is not a report or a meeting material but a specific announcement about share pledge changes. This fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding capital structure changes such as share pledges or releases.
2023-10-11 Chinese
北京安理（上海）律师事务所关于上海美迪西生物医药股份有限公司2023年第二次临时股东大会的法律意见书
Regulatory Filings
2023-09-26 Chinese
美迪西：2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 second extraordinary general meeting of shareholders of Shanghai Medicilon Inc. It details the meeting date, attendance, voting results, and legal compliance, including lawyer witness statements. The content focuses on the voting outcomes and procedural compliance of a shareholder meeting rather than presenting financial data or detailed reports. The document length is short (1411 characters) and it is clearly a resolution announcement from a shareholders meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-09-26 Chinese
美迪西：2023年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as meeting materials for the "2023 Second Extraordinary General Meeting of Shareholders" of Shanghai Medicilon Inc. It contains detailed information about the meeting agenda, procedures, voting rights, and a specific proposal regarding changes in registered capital and amendments to the company's articles of association. The content is focused on the meeting itself and the materials provided to shareholders for the meeting, rather than being a report of financial results or an announcement of voting results. The document length is about 5,077 characters, which is sufficient for detailed meeting materials. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or Extraordinary General Meeting. Therefore, the document should be classified as AGM Information (AGM-R).
2023-09-18 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司2023年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2023 Half-Year Continuous Supervision Tracking Report" issued by the sponsoring institution (广发证券股份有限公司) for Shanghai Medicilon Inc. It references regulatory frameworks related to securities issuance and listing supervision, and it provides detailed information on the supervision activities, risk factors, financial data for the first half of 2023, and compliance with fundraising usage. The document contains substantive financial data and analysis for the half-year period, including income, profit, assets, and other financial indicators. It is not merely an announcement or a certification but a comprehensive report on the half-year performance and supervision. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-09-13 Chinese
美迪西：独立董事关于第三届董事会第十七次会议相关事项的独立意见
Regulatory Filings
2023-09-07 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.